Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: A joint ITCC and SIOPE brain tumor study

Neuro-Oncology

Volumn 15, Issue 9, 2013, Pages 1236-1243

  Grill, Jacques ^a   Geoerger, Birgit ^a   Gesner, Lyle ^b   Perek, Danuta ^c   Leblond, Pierre ^d   Cañete, Adela ^e   Aerts, Isabelle ^f   Madero, Luis ^g   De Toledo Codina, Josep Sanchez ^h   Verlooy, Joris ⁱ   Estlin, Edward ^j   Cisar, Laura ^k   Breazna, Aurora ^k   Dorman, Andrew ^k   Bailey, Simon ^l   Nicolin, Gary ^m   Grundy, Richard G ⁿ   Hargrave, Darren ^o  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c Memorial Health Institute   (Poland)

^d CENTRE OSCAR LAMBRET   (France)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f INSTITUT CURIE   (France)

^g HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^k PFIZER INC   (United States)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

^m SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

ⁿ QUEEN S MEDICAL CENTRE   (United Kingdom)

^o INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

medulloblastoma; TEMIRI; temozolomide

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IRINOTECAN; METHOTREXATE; TEMOZOLOMIDE; THIOTEPA; VALPROIC ACID; VINCRISTINE;

ABDOMINAL PAIN; ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD; CHILDHOOD CANCER; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

MEDULLOBLASTOMA; TEMIRI; TEMOZOLOMIDE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; HUMANS; MALE; MEDULLOBLASTOMA;

EID: 84883169085     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not097     Document Type: Article

References (39)

1. Lafay-Cousin L, Strother D. Current treatment approaches for infants with malignant central nervous system tumors. Oncologist. 2009; 14:433-444.
2. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol. 2004;5:209-218. (Pubitemid 38391216)
3. von Hoff K, Hinkes B, Gerber NU, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT '91. Eur J Cancer. 2009;45:1209-1217.
4. Valteau-Couanet D, Fillipini B, Benhamou E, et al. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplant. 2005;36:939-945. (Pubitemid 41741555)
5. Rutkowski S, Cohen B, Finlay J, et al. Medulloblastoma in young children. Pediatr Blood Cancer. 2010;54:635-637.
6. Geoerger B, Chisholm J, Le Deley MC, et al. PhaseIIstudyof gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. Eur J Cancer. 2011;47:230-238.
7. Ruggiero A, Rizzo D, Attina G, et al. Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma. Eur J Cancer. 2010;46:2943-2949.
8. 6- benzylguanine in children with brain tumors: a Pediatric Brain Tumor Consortium report. Clin Cancer Res. 2007;13:6712-6718. (Pubitemid 350206808)
9. Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007;25:4622-4627. (Pubitemid 350035322)
10. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolo-mide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007; 110:1542-1550. (Pubitemid 47463069)
11. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomideinmalignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002;20:4684-4691. (Pubitemid 36025286)
12. Akyuz C, Demir HA, Varan A, et al. Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center. Childs Nerv Syst. 2011;28:111-115.
13. Wang CH, Hsu TR, Wong TT, Chang KP. Efficacy of temozolomide for recurrent embryonal brain tumors in children. Childs Nerv Syst. 2009;25:535-541.
14. De Sio L, Milano GM, Castellano A, et al. Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer. 2006;47:30-36. (Pubitemid 43787905)
15. Baruchel S, Diezi M, Hargrave D, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer. 2006;42:2335-2342. (Pubitemid 44316901)
16. Korones DN, Smith A, Foreman N, Bouffet E. Temozolomide and oral VP-16 for children and young adults with recurrentor treatment-induced malignant gliomas. Pediatr Blood Cancer. 2006;47:37-41. (Pubitemid 43787906)
17. Turner CD, Gururangan S, Eastwood J, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol. 2002;4:102-108. (Pubitemid 34285064)
18. Vassal G, Couanet D, Stockdale E, et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol. 2007;25:356-361. (Pubitemid 350002983)
19. Vassal G, Chastagner P, Doz F, et al. A phase II study of irinotecan (IRI) in children with relapsed or refractory CNS tumors (medulloblastoma and PNET). Proc Am Soc Clin Oncol. 2003;22:3235.
20. Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003;63:5738-5744. (Pubitemid 37187470)
21. Okamoto R, Takano H, Okamura T, et al. O(6)-methylguanine-DNA methyltransferase (MGMT)asadeterminantofresistancetocamptothecin derivatives. Jpn J Cancer Res. 2002;93:93-102.
22. Pourquier P, Waltman JL, Urasaki Y, et al. Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase Ibythe O6-methylguanine. Cancer Res. 2001;61:53-58. (Pubitemid 32095699)
23. Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repairphenotypes in xenograft models. Clin Cancer Res. 2000;6:4110-4118.
24. Patel VJ, Elion GB, Houghton PJ, et al. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res. 2000;6:4154-4157.
25. Reardon DA, Quinn JA, Rich JN, et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 2005;104:1478-1486. (Pubitemid 41356163)
26. Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) inadults with newly diagnosed glioblasto-ma multiforme before radiotherapy. J Neurooncol. 2009;95:393-400.
27. Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol. 2006;24:5271-5276. (Pubitemid 46631373)
28. Wagner LM, Crews KR, Iacono LC, et al. PhaseItrialoftemozolomideand protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res. 2004;10:840-848. (Pubitemid 38198882)
29. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48:132-139. (Pubitemid 44958268)
30. Simon R. Optimal two-stage designs for phaseIIclinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
31. Verschuur AC, Grill J, Lelouch-Tubiana A, et al. Temozolomide in paediatric high-grade glioma: a key for combination therapy? Br J Cancer. 2004;91:425-429. (Pubitemid 39093558)
32. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214. (Pubitemid 11167383)
33. Pizer B, Donachie PH, Robinson K, et al. Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children's Cancer and Leukaemia Group study. Eur J Cancer. 2011;47:1389-1397.
34. Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011;29:208-213.
35. Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer. 2010;103:1588-1596.
36. Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther. 2005; 4:1364-1368.
37. Zhang YW, Regairaz M, Seiler JA, et al. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res. 2011;39:3607-3620.
38. Tentori L, Leonetti C, Scarsella M, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J. 2006;20:1709-1711.
39. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther. 2003; 2:371-382.